Inflammatory Mechanisms and Oxidative Stress in Peyronies Disease: Therapeutic “Rationale” and Related Emerging Treatment Strategies
The DOI matches its Crossref record; 105 of the 105 references it cites were found in a registry or an index.
Abstract
Peyronie's disease (PD) is a connective tissue disorder characterized by a fibrous plaque involving the tunica albuginea of the penis. The inelastic fibrous plaque leads to a penile curvature. Several Authors have suggested an immunological genesis of this disease, others have linked PD with Dupuytren's contracture. Signs of this disease are curvature, penile pain, penile deformity, difficulty with coitus, shortening, hinging, narrowing and erectile dysfunction. The natural history of PD and the clinical course can develop from spontaneous resolution of symptoms to progressive penile deformity and impotence. Surgical treatment is indicated when patients fail the conservative medical treatment and however, only in case of disease stabilization with a condition of impossibility of penetration. The medical treatment is indicated in the development stage of PD for at least one year after diagnosis and whenever in case of penile pain. Current non-surgical therapy includes vitamin-E, verapamil, para-aminobenzoate, propoleum, colchicine, carnitine, tamoxifen, interferons, collagenase, hyaluronidase, cortisone, pentoxifylline, superoxide dismutase, iontophoresis, radiation, extracorporeal shock wave therapy (ESWT) and the penile extender. The etiology of this fibrotic disease is not widely known, although in recent years pathophysiological knowledge has evolved and new studies propose the penile trauma as cause of the disease. The penile trauma results in a delamination of the tunica albuginea with a consequent small hematoma, then the process evolves as an inflammation with accumulation of inflammatory cells and production of reactive oxygen species (ROS). In the course of the inflammation, Peyronie's disease occurs due to the activation of nuclear factor kappa-B, that induces the production of inducible nitric oxide synthase (iNOS), with an increase of nitric oxide, leading to increased production of peroxynitrite anion. All these processes result in the proliferation of fibroblasts and myo-fibroblasts and excessive production of collagen between the layers of the tunica albuginea (penile plaque). Referring to the current knowledge of inflammatory and oxidative mechanisms of PD, a possible therapeutic strategy is then analyzed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“At the same time, increased oxidative stress results in the production of reactive oxygen species, which causes cellular damage and worsens the fibrotic process.”
From Research advances in Peyronie's disease: a comprehensive review on genomics, pathways, phenotypic manifestation, and therapeutic targets. (2024) · cites this paper as [89]
In the citing paper
“Combination therapies may be a promising approach to enhance the effectiveness of treatment for PD.”
From Research advances in Peyronie's disease: a comprehensive review on genomics, pathways, phenotypic manifestation, and therapeutic targets. (2024) · cites this paper as [89]
In the citing paper
“By combining drugs that target different signaling pathways or disease processes, a more comprehensive therapeutic effect can be achieved, addressing multiple aspects of the disease progression.38,48,89,122”
From Research advances in Peyronie's disease: a comprehensive review on genomics, pathways, phenotypic manifestation, and therapeutic targets. (2024) · cites this paper as [89]
In the citing paper
“PD progresses in two main stages. The first phase typically lasts between 12 and 18 months; this phase is the “active inflammatory phase”, in which plaque forms and progresses to fibrosis and potential calcification, accompanied by pain and worsening of the penile deformity. In the second phase, known as the chronic “stabilized phase”, penile pain decreases and the plaque size and deformity stabil”
From Clinical Presentation of Peyronie’s Disease: A Retrospective Study of 564 Cases (2024) · cites this paper as [19]
In the citing paper
“In the scientific literature, several articles have appeared in the 21st century that have clarified the important role that “oxidative stress” plays in the pathophysiology of PD [15,16,17,18,19,20,21,22].”
From Clinical Presentation of Peyronie’s Disease: A Retrospective Study of 564 Cases (2024) · cites this paper as [19]
Citations
Cites
1 retracted
Safarinejad, M. R., Asgari, M. A., Hosseini, S. Y., & Dadkhah, F. (2010) · BJU International · doi:10.1111/j.1464-410x.2009.09041.x · Cited by 77 · cited 1×
“A double-blind placebo-controlled study in men with PD, has shown that PTX (400 mg/ oral / twice daily / 6 months) was moderately effective in reducing penile curvature and plaque size [88]; however the results were statistically significant.”
BackgroundRetractedNatarajan, K., Singh, S., Burke, T. R., Grunberger, D., & Aggarwal, B. B. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.17.9090 · Cited by 1,139 · cited 1×
“Propolis, mainly due to its component CAPE, inhibits NF- B activity and the production of interleukins [78-80].”
BackgroundThe Natural History of Peyronie’s Disease
Gelbard, M. K., Dorey, F., & James, K. (1990) · Journal of Urology · doi:10.1016/s0022-5347(17)39746-x · Cited by 525
STRYKER, W. S., KAPLAN, L. A., STEIN, E. A., STAMPFER, M. J., SOBER, A., & WILLETT, W. C. (1988) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a114804 · Cited by 521 · cited 1×
“We believe that the discovery of this association is due to the well-known adverse effects of cigarette smoking on the antioxidant defense system [15-18].”
BackgroundLi, Y., Foster, W., Deasy, B. M., Chan, Y., Prisk, V., Tang, Y., Cummins, J., & Huard, J. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63188-4 · Cited by 451
The prevalence of Peyronie's disease: results of a large survey
Schwarzer, U., Sommer, F., Klotz, T., Braun, M., Reifenrath, B., & Engelmann, U. (2001) · BJU International · doi:10.1046/j.1464-4096.2001.02436.x · Cited by 440
An Analysis of the Natural History of Peyronie’s Disease
Mulhall, J. P., Schiff, J., & Guhring, P. (2006) · Journal of Urology · doi:10.1016/s0022-5347(06)00270-9 · Cited by 417 · cited 1×
“Though some studies reported the spontaneous resolution in patients without any therapy [23, 24], other authors have achieved a worsening of the penile curvature, respectively, in 30,2% and 48% of cases at follow-up [25, 26].”
ResultMULHALL, J. P., CREECH, S. D., BOORJIAN, S. A., GHALY, S., KIM, E. D., MOTY, A., DAVIS, R., & HELLSTROM, W. (2004) · Journal of Urology · doi:10.1097/01.ju.0000127744.18878.f1 · Cited by 385
Karlsen, A., Retterstøl, L., Laake, P., Paur, I., Kjølsrud-Bøhn, S., Sandvik, L., & Blomhoff, R. (2007) · The Journal of Nutrition · doi:10.1093/jn/137.8.1951 · Cited by 384 · cited 1×
“Blueberry anthocyanins (flavonoids) inhibit NF- B, iNOS and COX-2 expression [116, 117].”
BackgroundProposal: Trauma as the Cause of the Peyronie's Lesion
Devine, C. J. J., Somers, K. D., Jordan, G. H., & Schlossberg, S. M. (1997) · Journal of Urology · doi:10.1016/s0022-5347(01)65361-8 · Cited by 381 · cited 1×
“The etiology of this fibrotic disease is not widely known, although in recent years pathophysiological knowledge has evolved and new studies propose the penile trauma (micro- or macro-trauma) as cause of the disease [19,20].”
Background
Cited by
d'Agostino, M. C., Craig, K., Tibalt, E., & Respizzi, S. (2015) · International Journal of Surgery · doi:10.1016/j.ijsu.2015.11.030 · Cited by 287
Adipose Tissue Dysfunction and Obesity-Related Male Hypogonadism
Genchi, V. A., Rossi, E., Lauriola, C., D’Oria, R., Palma, G., Borrelli, A., Caccioppoli, C., Giorgino, F., & Cignarelli, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158194 · Cited by 175
Lipshultz, L. I., Goldstein, I., Seftel, A. D., Kaufman, G. J., Smith, T. M., Tursi, J. P., & Burnett, A. L. (2015) · BJU International · doi:10.1111/bju.13096 · Cited by 120
Paulis, G., Brancato, T., D'Ascenzo, R., De Giorgio, G., Nupieri, P., Orsolini, G., & Alvaro, R. (2013) · Andrology · doi:10.1111/j.2047-2927.2012.00007.x · Cited by 67
“…many recent studies have demonstrated the efficacy of several substances with anti-oxidative activity (propolis, carnitine, pentoxifylline, coenzyme Q10, blueberry flavonoids etc.) in the treatment of PD (Cavallini et al., 2002; Safarinejad, 2010b; Safarinejad et al., 2010a; Paulis et al., 2012).”
BackgroundSelf-citationNonsurgical management of Peyronie’s disease
Tsambarlis, P., & Levine, L. A. (2019) · Nature Reviews Urology · doi:10.1038/s41585-018-0117-7 · Cited by 64
Metadata
- Authors
- Paulis, G., & Brancato, T.
- Affiliations
- Ospedale Regina Apostolorum (IT)
- ORCID
- Paulis, Gianni
- Venue
- Inflammation & Allergy - Drug Targets
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2012-02-01
- Volume
- 11
- Issue
- 1
- Pages
- 48-57
- ISSN
- 1871-5281 (ISSN-L)
- OpenAlex
- W2025237264
- Cited by
- 60
- References
- 103
- Citations by year
- 2026: 4 · 2025: 3 · 2024: 6 · 2023: 2 · 2022: 4 · 2021: 4 · 2020: 3 · 2019: 3 · 2018: 4 · 2017: 2 · 2016: 6 · 2015: 9 · 2014: 3 · 2013: 5 · 2012: 2
- FWCI
- 4.66
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Inflammation & Allergy - Drug Targets (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Rheumatology › Dupuytren's Contracture and Treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Sexual function and dysfunction studies
- Health Sciences › Medicine › Urology › Urological Disorders and Treatments
- Keywords
- Peyronie's disease, tunica albuginea fibrosis, penile curvature, oxidative stress, reactive oxygen species, NF-κB, inducible nitric oxide synthase, nitric oxide, peroxynitrite, myofibroblast proliferation, collagen deposition, penile trauma, extracorporeal shock wave therapy, verapamil, collagenase, hyaluronidase, pentoxifylline, iontophoresis, corticosteroids, interferon, tamoxifen
- MeSH terms
- Animals, Colchicine, Humans, Inflammation, Male, Penile Induration, Penis, Verapamil, Vitamin E, Treatment Outcome, Reactive Oxygen Species, Oxidative Stress
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inflammatory Mechanisms and Oxidative Stress in Peyronies Disease: Therapeutic “Rationale” and Related Emerging Treatment Strategies. https://app.cochat.ai/papers/10.2174/187152812798889321
- The paper
- Paulis, G., & Brancato, T. (2012). Inflammatory Mechanisms and Oxidative Stress in Peyronies Disease: Therapeutic “Rationale” and Related Emerging Treatment Strategies. Inflammation & Allergy - Drug Targets. https://doi.org/10.2174/187152812798889321
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.